# Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

> **NCT00184067** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 23 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Montanide ISA 51

## Key facts

- **NCT ID:** NCT00184067
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2007-04
- **Final completion:** 2009-09
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Primary PI left institution
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184067, "Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00184067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*